throbber
IPR2015-00554
` Patent No. 7,668,730
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`AMNEAL PHARMACEUTICALS, LLC and
`PAR PHARMACEUTICAL, INC.
`Petitioner
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`Patent Owner
`
`
`
`
`
`
`
`
`
`_____________________
`
`Case IPR2015-00554
`Patent 7,668,730
`_____________________
`
`PETITIONERS’ OBJECTIONS TO EVIDENCE SUBMITTED DURING THE
`PRELIMINARY PROCEEDING PURSUANT TO 37 C.F.R. § 42.64(B)(1)
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`

`
`
`
`
`IPR2015-00554
` Patent No. 7,668,730
`
`Pursuant to 37 C.F.R. §42.64(b)(1), Petitioners Amneal Pharmaceuticals
`
`LLC and Par Pharmaceutical, Inc. object as follows to the admissibility of
`
`evidence submitted during the preliminary proceeding:
`
`1.
`
`JAZZ EXHIBIT 2015 is objected to under Fed. R. Ev. 401–402
`
`because the Exhibit does nothing to show that Par Pharmaceutical Holdings, Inc.
`
`has any relation, direction, or control over this proceeding, and is thus irrelevant to
`
`the question of whether Par Pharmaceutical Holdings, Inc. is a real-party-in-
`
`interest in this proceeding. JAZZ EXHIBIT 2015 is also objected to under Fed. R.
`
`Ev. 403 because its minimal probative value is substantially outweighed by the fact
`
`that it is misleading and needlessly cumulative.
`
`2.
`
`JAZZ EXHIBIT 2016 is objected to under Fed. R. Ev. 401–402
`
`because the Exhibit does nothing to show that Par Pharmaceutical Companies, Inc.
`
`has any relation, direction, or control over this proceeding, and is thus irrelevant to
`
`the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-
`
`interest in this proceeding. JAZZ EXHIBIT 2016 is also objected to under Fed. R.
`
`Ev. 403 because its minimal probative value is substantially outweighed by the fact
`
`that it is misleading and needlessly cumulative.
`
`3.
`
`JAZZ EXHIBIT 2017 is objected to under Fed. R. Ev. 401–402
`
`because the section of website presented does nothing to show that Par
`
`
`
`- 1 -
`
`

`
`
`Pharmaceutical Companies, Inc. has any relation, direction, or control over this
`
`IPR2015-00554
` Patent No. 7,668,730
`
`proceeding, and is thus irrelevant to the question of whether Par Pharmaceutical
`
`Companies, Inc. is a real-party-in-interest in this proceeding. JAZZ EXHIBIT
`
`2017 is also objected to under Fed. R. Ev. 403 because its minimal probative value
`
`is substantially outweighed by the fact that it is misleading and needlessly
`
`cumulative.
`
`4.
`
`JAZZ EXHIBIT 2018 is objected to under Fed. R. Ev. 401–402
`
`because the Exhibit does nothing to show that Par Pharmaceutical Companies, Inc.
`
`has any relation, direction, or control over this proceeding, and is thus irrelevant to
`
`the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-
`
`interest in this proceeding. JAZZ EXHIBIT 2018 is also objected to under Fed. R.
`
`Ev. 403 because its minimal probative value is substantially outweighed by the fact
`
`that it is misleading and needlessly cumulative.
`
`5.
`
`JAZZ EXHIBIT 2019 is objected to under Fed. R. Ev. 401–402
`
`because the Exhibit does nothing to show that Par Pharmaceutical Companies, Inc.
`
`has any relation, direction, or control over this proceeding, and is thus irrelevant to
`
`the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-
`
`interest in this proceeding. JAZZ EXHIBIT 2019 is also objected to under Fed. R.
`
`Ev. 403 because its minimal probative value is substantially outweighed by the fact
`
`that it is misleading and needlessly cumulative.
`
`
`
`- 2 -
`
`

`
`6.
`
`JAZZ EXHIBIT 2020 is objected to under Fed. R. Ev. 401–402
`
`IPR2015-00554
` Patent No. 7,668,730
`
`
`
`because the Exhibit does nothing to show that Par Pharmaceutical Companies, Inc.
`
`has any relation, direction, or control over this proceeding, and is thus irrelevant to
`
`the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-
`
`interest in this proceeding. JAZZ EXHIBIT 2020 is also objected to under Fed. R.
`
`Ev. 403 because its minimal probative value is substantially outweighed by the fact
`
`that it is misleading and needlessly cumulative.
`
`7.
`
`JAZZ EXHIBIT 2021 is objected to under Fed. R. Ev. 401–402
`
`because the Exhibit does nothing to show that Par Pharmaceutical Holdings, Inc.
`
`has any relation, direction, or control over this proceeding, and is thus irrelevant to
`
`the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-
`
`interest in this proceeding. JAZZ EXHIBIT 2021 is also objected to under Fed. R.
`
`Ev. 403 because its minimal probative value is substantially outweighed by the fact
`
`that it is misleading and needlessly cumulative.
`
`8.
`
`JAZZ EXHIBIT 2023 is objected to under Fed. R. Ev. 401 because
`
`the Exhibit here does nothing to show that Par Pharmaceutical Companies, Inc. has
`
`any relation, direction, or control over this proceeding, and is thus irrelevant to the
`
`question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-interest
`
`in this proceeding. JAZZ EXHIBIT 2023 is also objected to under Fed. R. Ev.
`
`403 because its minimal probative value is substantially outweighed by the fact
`
`
`
`- 3 -
`
`

`
`
`that it is misleading and needlessly cumulative.
`
`IPR2015-00554
` Patent No. 7,668,730
`
`9.
`
`JAZZ EXHIBIT 2025 is objected to under Fed. R. Ev. 401 because
`
`the Exhibit here does nothing to show that Par Pharmaceutical Companies, Inc. has
`
`any relation, direction, or control over this proceeding, and is thus irrelevant to the
`
`question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-interest
`
`in this proceeding. JAZZ EXHIBIT 2025 is also objected to under Fed. R. Ev.
`
`403 because its minimal probative value is substantially outweighed by the fact
`
`that it is misleading, confusing the issues, and needlessly cumulative. JAZZ
`
`EXHIBIT 2025 is also objected to under Fed. R. Ev. 802 as impermissible
`
`hearsay, as it is a statement offered by Jazz Pharmaceuticals, Inc. in an attempt to
`
`prove the truth of the matter asserted therein, including, but not limited to, that
`
`David Silverstein is employed by Par Pharmaceutical Companies, Inc.
`
`10.
`
`JAZZ EXHIBIT 2026 is objected to under Fed. R. Ev. 401–402
`
`because the Exhibit is a Complaint is for a proceeding unrelated to the present
`
`Petition, and fails to in any way demonstrate that Par Pharmaceutical Companies,
`
`Inc. has any direction or control over the instant Petition or proceedings sufficient
`
`to make them a real party in interest. JAZZ EXHIBIT 2026 is also objected to
`
`under Fed. R. Ev. 403 because its minimal probative value is substantially
`
`outweighed by the fact that it is misleading and needlessly cumulative.
`
`11.
`
`JAZZ EXHIBIT 2027 is objected to under Fed. R. Ev. 401–402
`
`
`
`- 4 -
`
`

`
`
`because the Exhibit is a Complaint is for a proceeding unrelated to the present
`
`IPR2015-00554
` Patent No. 7,668,730
`
`Petition, and fails to in any way demonstrate that Par Pharmaceutical Companies,
`
`Inc. has any direction or control over the instant Petition or proceedings sufficient
`
`to make them a real party in interest. JAZZ EXHIBIT 2027 is also objected to
`
`under Fed. R. Ev. 403 because its minimal probative value is substantially
`
`outweighed by the fact that it is misleading and needlessly cumulative.
`
`12.
`
`JAZZ EXHIBIT 2034 is objected to under Fed. R. Ev. 401 because
`
`the LinkedIn page presented here does nothing to show that Par Pharmaceutical
`
`Companies, Inc. has any relation, direction, or control over this proceeding, and is
`
`thus irrelevant to the question of whether Par Pharmaceutical Companies, Inc. is a
`
`real-party-in-interest in this proceeding. JAZZ EXHIBIT 2034 is also objected to
`
`under Fed. R. Ev. 403 because its minimal probative value is substantially
`
`outweighed by the fact that it is misleading, confusing the issues, and needlessly
`
`cumulative. JAZZ EXHIBIT 2034 is also objected to under Fed. R. Ev. 802 as
`
`impermissible hearsay, as it is a statement offered by Jazz Pharmaceuticals, Inc. in
`
`an attempt to prove the truth of the matter asserted therein, including, but not
`
`limited to, that Barry Gilman is employed by Par Pharmaceutical Companies, Inc.
`
`13.
`
`JAZZ EXHIBIT 2036 is objected to under Fed. R. Ev. 401 because
`
`the LinkedIn page presented here does nothing to show that Par Pharmaceutical
`
`Companies, Inc. has any relation, direction, or control over this proceeding, and is
`
`
`
`- 5 -
`
`

`
`
`thus irrelevant to the question of whether Par Pharmaceutical Companies, Inc. is a
`
`IPR2015-00554
` Patent No. 7,668,730
`
`real-party-in-interest in this proceeding. JAZZ EXHIBIT 2036 is also objected to
`
`under Fed. R. Ev. 403 because its minimal probative value is substantially
`
`outweighed by the fact that it is misleading, confusing the issues, and needlessly
`
`cumulative. JAZZ EXHIBIT 2036 is also objected to under Fed. R. Ev. 802 as
`
`impermissible hearsay, as it is a statement offered by Jazz Pharmaceuticals, Inc. in
`
`an attempt to prove the truth of the matter asserted therein, including, but not
`
`limited to, that Suketu Sanghvi is employed by Par Pharmaceutical, Inc.
`
`
`
`Respectfully Submitted,
`
`Aziz Burgy
`Registration No. 51,514
`Attorney for Petitioner
`
`
`
`
`
`
`
`Date: August 11, 2015
`ARENT FOX LLP
`1717 K Street, NW
`Washington, DC 20006
`202.857.6000
`
`
`
`- 6 -
`
`

`
`CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e), 42.105(a))
`
`IPR2015-00554
` Patent No. 7,668,730
`Certificate of Service
`
`
`The undersigned hereby certifies that the above-captioned PETITIONERS’
`
`OBJECTIONS TO EVIDENCE SUBMITTED DURING THE PRELIMINARY
`
`PROCEEDING PURSUANT TO 37 C.F.R. § 42.64(B)(1), was served in its
`
`entirety on August 11, 2015, upon the following parties via Electronic Mail:
`
`F. Dominic Cerrito
`QUINN EMANUEL URQUHART &
`SULLIVAN LLP
`51 Madison Avenue
`22nd Floor
`New York, NY 10010
`NickCerrito@quinnemanuel.com
`
`John V. Biernacki
`Jones Day
`North Point
`901 Lakeside Avenue
`Cleveland, OH 44114
`JVBiernacki@JonesDay.Com
`
`
`
`
`
`
`- 1 -
`
`

`
`
`
`IPR2015-00554
` Patent No. 7,668,730
`Certificate of Service
`
`
`Respectfully Submitted,
`
`Aziz Burgy
`Registration No. 51,514
`Attorney for Petitioner
`
`
`
`
`
`- 2 -
`
`
`
`Date: August 11, 2015
`ARENT FOX LLP
`1717 K Street, NW
`Washington, DC 20006
`202.857.6000

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket